Does insurance cover Ozempic?

If you’re considering GLP-1 medications like Wegovy, Ozempic, or Mounjaro for weight loss, one of your first questions is likely: ‘Will my insurance cover this?’ The answer isn’t straightforward—coverage varies dramatically based on your insurance type, diagnosis, state, and even your employer’s specific plan. With monthly costs reaching over $1,000 without insurance, understanding your coverage options is essential before starting treatment.

This guide breaks down everything you need to know about insurance coverage for GLP-1 weight loss medications, including what to expect from commercial insurance, Medicare, and Medicaid, common reasons for denials, and your best options if coverage is denied.

Understanding GLP-1 Medications: Three Drugs, Different Coverage Rules

Before diving into insurance specifics, it’s important to understand that not all GLP-1 medications have the same coverage landscape:

Wegovy (semaglutide) is FDA-approved specifically for chronic weight management. This is the medication most people think of for weight loss, but it’s also the one with the most coverage restrictions. Many insurance plans exclude or severely limit coverage for medications prescribed solely for weight loss, regardless of medical necessity.

Ozempic (semaglutide) is FDA-approved for Type 2 diabetes, not weight loss. While it contains the same active ingredient as Wegovy, insurers generally only cover Ozempic when prescribed for diabetes management. Using Ozempic ‘off-label’ for weight loss typically results in coverage denial, though some patients and providers pursue this route when Wegovy isn’t covered.

Mounjaro (tirzepatide) is also approved for Type 2 diabetes. Like Ozempic, it’s widely covered for diabetes treatment but not for weight loss alone. (Zepbound, the weight-loss version of tirzepatide, faces similar coverage challenges as Wegovy.)

The key takeaway: Diabetes indication = better coverage. Weight loss indication = significant barriers.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Commercial Insurance Coverage: What to Expect

Coverage for Diabetes vs. Weight Loss

If you have commercial insurance through your employer or the ACA marketplace, coverage depends heavily on why you’re taking the medication:

For Type 2 diabetes: Ozempic and Mounjaro are typically covered as essential pharmacy benefits. You’ll likely need prior authorization to confirm your diagnosis, and you may need to demonstrate that you’ve tried first-line treatments like metformin. Most plans place these medications in Tier 3 (non-preferred brand) or Tier 4 (specialty), meaning higher copays—often $50–$150 or 20–40% coinsurance.

For weight loss: Coverage becomes far more complicated. Many employer plans treat anti-obesity medications as ‘optional benefits’ due to their high cost. Even when Wegovy is on your formulary, expect strict requirements:

• BMI threshold: Usually ≥30, or ≥27 with at least one weight-related comorbidity (like hypertension, high cholesterol, or sleep apnea)
• Documented lifestyle attempts: Most insurers require proof of at least 6 months of supervised diet and exercise programs
• Step therapy: Some plans require you to try older, cheaper weight-loss medications first
• Age restrictions: Typically limited to adults 18 and older (though some cover adolescents 12+ under specific criteria)
• Quantity limits: Usually 4 pens per 28 days, matching FDA dosing schedules
• Ongoing monitoring: Many plans require periodic check-ins to demonstrate at least 5% weight loss to continue coverage

Real-World Coverage Scenarios

According to recent data, the majority of large employer plans now include some coverage for GLP-1 weight loss medications, but ‘coverage’ doesn’t mean easy access. A 2024 Kaiser Family Foundation analysis found that while coverage is expanding in commercial insurance, prior authorization requirements are nearly universal, and many patients face denials on their first attempt.

Example scenarios:

• Large employer with comprehensive benefits: May cover Wegovy with a $75 specialty copay after meeting PA requirements
• Small employer plan: May exclude all weight-loss medications from coverage entirely
• ACA marketplace plan: Coverage varies by carrier; some exclude obesity drugs completely, while others cover them with strict criteria

How Klarity Health Can Help

Navigating insurance requirements for weight-loss medications can be overwhelming. Klarity Health’s experienced providers understand exactly what documentation insurers need for prior authorization. During your telehealth visit, your provider can:

• Document your BMI and weight-related health conditions accurately
• Create a comprehensive treatment plan that meets insurance criteria
• Submit prior authorization requests with all necessary clinical justification
• Help you explore alternative coverage pathways if your first request is denied

Klarity Health accepts most major insurance plans and also offers transparent cash-pay options if insurance coverage isn’t available. With provider availability that works around your schedule, you can start your weight management journey without the typical delays of traditional healthcare.

Medicare Coverage: Limited and Specific

Medicare’s coverage of GLP-1 medications is governed by federal law, which creates significant limitations:

The Medicare Coverage Gap

Under the Social Security Act, Medicare Part D cannot cover drugs used solely for weight loss or weight management. This federal exclusion means that traditional Medicare will not cover Wegovy, Zepbound, or similar medications prescribed for obesity treatment—regardless of medical necessity.

However, there’s an important exception: Medicare will cover these medications when prescribed for other FDA-approved uses. Since March 2024, Medicare covers Wegovy for cardiovascular risk reduction in patients with obesity and established cardiovascular disease. This means if you’re obese, have had a heart attack or stroke, and meet clinical criteria, Wegovy may be covered—but the indication must be cardiovascular protection, not weight loss per se.

For diabetes: Ozempic and Mounjaro are covered under Medicare Part D when prescribed for Type 2 diabetes, typically with:

• Prior authorization confirming diabetes diagnosis
• Placement in higher formulary tiers (often Tier 3–4)
• Step therapy requirements (must try metformin or other first-line agents first)

Medicare Advantage Plans

Some Medicare Advantage plans have begun offering limited coverage for weight-loss medications as supplemental benefits beyond what traditional Medicare provides. However, this varies dramatically by plan and region, and such coverage usually comes with:

• High out-of-pocket costs
• Very strict medical necessity criteria
• Limited formulary access (not all MA plans offer this)

Bottom line for Medicare beneficiaries: Don’t expect coverage for weight-loss GLP-1s unless you have a specific covered indication like cardiovascular disease. For diabetes treatment, coverage mirrors that of commercial plans.

Medicaid Coverage: A State-by-State Patchwork

Medicaid coverage of GLP-1 weight-loss medications varies enormously by state, and the landscape is rapidly changing—mostly in a restrictive direction due to budget pressures.

The Current State of Medicaid Coverage

As of late 2025, only about 13 states provide Medicaid coverage for anti-obesity medications like Wegovy. Even in states that cover these drugs, access is tightly controlled through prior authorization requirements that mirror or exceed those of commercial insurance.

States that currently cover weight-loss GLP-1s (with strict PA criteria):

• New York
• Pennsylvania (though coverage will end January 2026)
• North Carolina
• Louisiana
• Minnesota
• A handful of others

States that explicitly do not cover (utilizing federal optional exclusion):

• California (coverage ending January 1, 2026)
• Texas
• Florida
• Illinois
• And many others

Priority State Details

Why Coverage Is Disappearing

States face enormous budget pressures from GLP-1 medications. California’s decision to end coverage was driven by projected costs exceeding $1 billion annually. Pennsylvania cited similar fiscal concerns. Even states that want to provide access struggle with the financial reality of covering medications that cost $1,000+ per month per patient.

Important exception: Even in states that don’t cover obesity medications for adults, children and adolescents under 21 may still access these medications through EPSDT (Early and Periodic Screening, Diagnostic, and Treatment) benefits, which require states to cover medically necessary treatments for minors.

Common Reasons for Coverage Denial (And How to Overcome Them)

Understanding why insurance denies coverage helps you prepare a stronger initial request and more effective appeals:

1. Insufficient BMI or Missing Comorbidities

Why it happens: Your documented BMI doesn’t meet the plan’s threshold (usually ≥30, or ≥27 with qualifying conditions), or required comorbidities aren’t clearly documented.

Solution: Ensure your provider documents your current weight, height, calculated BMI, and all relevant health conditions (hypertension, high cholesterol, sleep apnea, Type 2 diabetes, etc.) in the prior authorization request. If you’re close to the BMI threshold, have your weight checked on a calibrated medical scale.

2. Lack of Documented Lifestyle Intervention

Why it happens: Most insurers require proof of at least 6 months of supervised diet and exercise attempts before approving medication.

Solution: Your provider needs to document past weight-loss attempts, including dates, methods, and outcomes. This might include nutritional counseling records, gym memberships, medically supervised diet programs, or weight-loss medication trials. If you haven’t done a formal program, some providers can document your self-directed attempts with physician oversight, though this may be less likely to succeed.

3. Step Therapy Not Completed

Why it happens: Your plan requires trying cheaper alternatives first—either older weight-loss medications (like phentermine, orlistat) or, for diabetes patients, trying a preferred GLP-1 before a non-preferred one.

Solution: Work with your provider to either complete the required step therapy or document medical reasons why those alternatives are inappropriate (contraindications, prior adverse reactions, etc.). Sometimes a detailed letter of medical necessity can justify skipping step therapy.

4. Off-Label Use

Why it happens: You’re prescribed Ozempic or Mounjaro for weight loss when you don’t have Type 2 diabetes, or Wegovy is being requested for a non-approved use.

Solution: If you don’t have diabetes, Ozempic won’t be covered for weight loss—period. You’ll need to request Wegovy instead and meet obesity criteria. If you do have both diabetes and obesity, your provider should prescribe based on the primary indication (usually the diabetes medication, which may also result in weight loss).

5. Plan Exclusion

Why it happens: Your insurance policy simply doesn’t cover weight-loss medications, regardless of medical necessity. This is common with employer plans that opted out of obesity drug coverage due to cost.

Solution: Unfortunately, appeals rarely succeed when there’s a blanket exclusion. Your options are to pay out-of-pocket, use manufacturer savings programs, change insurance during open enrollment, or explore whether a different medication indication might qualify (for example, getting Ozempic covered if you develop prediabetes).

The Prior Authorization Process: What to Expect

Prior authorization (PA) for GLP-1 medications typically works like this:

1. Initial prescription: Your provider prescribes the medication and submits a PA request to your insurance.

2. Documentation submitted: The PA includes your medical records, BMI calculation, comorbidities, past weight-loss attempts, and clinical justification.

3. Insurance review: The plan reviews the request against their criteria (usually within 5–7 business days for standard requests; 72 hours for urgent requests).

4. Decision: You’ll receive approval (sometimes for a limited duration like 3–6 months), denial with specific reasons, or a request for more information.

5. Appeal if denied: If denied, you have the right to appeal, usually within 60–180 days depending on your plan. Your provider can submit additional documentation or a letter of medical necessity.

Timeline: Expect the initial PA process to take 1–2 weeks. Appeals can take 2–4 weeks. Some plans offer expedited reviews for urgent medical situations.

Self-Pay Options When Insurance Won’t Cover

If insurance denies coverage or you don’t have insurance, several programs can significantly reduce your out-of-pocket costs:

Manufacturer Savings Programs

Novo Nordisk (Wegovy, Ozempic):

• Commercial insurance copay card: Can reduce your copay to as low as $0 (with maximum savings of $225/month) if you have private insurance
• Cash-pay program: Wegovy now available for $349/month through Novo’s self-pay program (down from the ~$1,350 list price)
• Patient Assistance Program: Free medication for qualifying uninsured or underinsured patients based on income

Eli Lilly (Mounjaro, Zepbound):

• Savings card: $25/month for commercially insured patients with Type 2 diabetes
• Self-pay vials: Zepbound single-dose vials starting at $299–$449/month through LillyDirect
• Patient Assistance Program: Free medication for eligible patients meeting income criteria

GoodRx and Discount Programs

In November 2025, GoodRx announced a groundbreaking partnership with Novo Nordisk:

• Introductory pricing: Wegovy and Ozempic available for $199/month for the first two months
• Ongoing pricing: Approximately $349/month afterward
• Availability: At nearly all U.S. pharmacies using the GoodRx discount

This represents a 60–70% discount from list prices and is currently the best cash-pay option for many patients without insurance coverage.

Comparison of Self-Pay Options

Important notes:

• Manufacturer copay cards typically can’t be used with government insurance (Medicare, Medicaid)
• Patient assistance programs have income limits (usually around 400% of federal poverty level)
• Prices and programs change frequently—always verify current offers

Telehealth and Insurance: Getting Virtual Care Covered

Good news for those seeking convenient care: telehealth visits for weight management are typically covered by insurance just like in-person visits.

Telehealth Parity Laws

More than 40 states have enacted telehealth parity laws requiring private insurers to cover virtual care equivalently to in-person services. Since the COVID-19 pandemic, Medicare and most commercial plans have maintained expanded telehealth coverage.

What this means for you:

• Initial consultations for weight management can be conducted virtually
• Follow-up visits to monitor medication effectiveness are covered
• Nutritional counseling (often a required component of obesity treatment) can be done via telehealth
• Most major insurers now contract with telehealth platforms or allow your provider to conduct virtual visits

Insurance Considerations for Telehealth

Check these details with your plan:

• Network status: Is your telehealth provider in-network? (Out-of-network may have higher costs or no coverage)
• Visit type: Some plans require live video visits rather than phone-only consultations
• State licensing: Your provider must be licensed in your state
• Prescription coverage: Even if the telehealth visit is cash-pay, your prescription might still be covered by insurance if it meets PA requirements

How Klarity Health works with insurance:Klarity Health accepts both insurance and cash pay, providing flexibility based on your coverage situation. Your provider can submit prior authorizations on your behalf and work directly with your insurance to maximize coverage. With transparent pricing and provider availability that fits your schedule, you can access expert weight management care without the typical barriers of traditional healthcare.

Coverage Comparison Table: What’s Covered Where

Steps to Maximize Your Chances of Coverage Approval

Based on successful appeals and coverage experiences, here’s your action plan:

Before Your Provider Visit

1. Review your insurance formulary to see if the medication is listed
2. Read your plan’s medical policy for obesity or diabetes drugs (usually available on your insurer’s website)
3. Gather documentation of past weight-loss attempts, current health conditions, and medication history
4. Calculate your BMI and know your comorbidities

During Your Visit

1. Be honest and thorough about your medical history
2. Discuss all weight-related health conditions (even if they seem minor)
3. Ask your provider about PA requirements specific to your insurance
4. Ensure accurate documentation of your BMI, weight history, and previous interventions

After Prescription

1. Follow up on PA status within a few days
2. If denied, request the specific denial reason immediately
3. File an appeal within the deadline (typically 60–180 days)
4. Provide additional documentation if requested
5. Consider a peer-to-peer review where your doctor speaks directly with the insurance medical reviewer

If All Else Fails

1. Explore manufacturer assistance programs
2. Use prescription discount cards (GoodRx, SingleCare)
3. Ask about alternative medications that might have better coverage
4. Consider switching insurance during open enrollment if weight-loss coverage is a priority
5. Look into cash-pay telehealth services with transparent pricing

The Bottom Line on GLP-1 Insurance Coverage

Insurance coverage for GLP-1 weight-loss medications remains complicated and highly variable as of 2025. While diabetes indications (Ozempic, Mounjaro) generally receive coverage through commercial insurance and Medicare Part D, weight-loss indications (Wegovy, Zepbound) face significant barriers.

Key takeaways:

✅ Commercial insurance: May cover with strict requirements—expect prior authorization, BMI thresholds, lifestyle documentation, and possible step therapy

✅ Medicare: Covers for diabetes; very limited coverage for weight loss (only specific cardiovascular indications)

✅ Medicaid: State-dependent and shrinking; only about 13 states cover, and several are ending programs in 2026

✅ Self-pay options: Dramatically improved in late 2025, with GoodRx offering $199–$349/month pricing and manufacturers offering assistance programs

✅ Telehealth: Widely covered by insurance when using in-network providers; convenient option for obtaining care and prescriptions

Most important: Don’t assume your first answer is final. Many patients receive coverage approval on appeal with proper documentation. Work with an experienced provider who understands insurance requirements—like the clinicians at Klarity Health—to navigate the prior authorization process successfully.

Whether you’re working with insurance or exploring cash-pay options, effective weight management with GLP-1 medications is more accessible than ever. The key is understanding your options, preparing thorough documentation, and advocating for your health needs.

Ready to Start Your Weight Loss Journey?

Klarity Health makes accessing GLP-1 weight-loss medications straightforward—whether through insurance or cash pay.

• ✅ Experienced providers who understand insurance requirements
• ✅ Comprehensive prior authorization support
• ✅ Accept most major insurance plans
• ✅ Transparent cash-pay pricing if insurance doesn’t cover
• ✅ Convenient telehealth visits that fit your schedule
• ✅ No lengthy wait times—get started this week

Schedule your consultation today and take the first step toward effective, medically supervised weight management.

Frequently Asked Questions

Q: Will my insurance cover Ozempic for weight loss if I don’t have diabetes?

A: Almost certainly not. Ozempic is FDA-approved only for Type 2 diabetes, and insurers deny coverage for off-label weight-loss use. You would need to request Wegovy instead and meet obesity treatment criteria.

Q: How long does prior authorization take?

A: Standard requests typically receive decisions within 5–7 business days. Urgent requests may be processed within 72 hours. Appeals can take 2–4 weeks.

Q: Can I use a manufacturer savings card if I have insurance that doesn’t cover the medication?

A: This varies by program. Some manufacturer cards work even if your plan doesn’t cover the drug, as long as you have commercial (non-government) insurance. Check the specific program’s eligibility requirements.

Q: What happens if my state Medicaid doesn’t cover Wegovy?

A: You’ll need to pay out-of-pocket or apply for manufacturer patient assistance programs if you meet income criteria. You might also ask your provider about older, less expensive weight-loss medications that Medicaid might cover.

Q: Are compounded semaglutide or tirzepatide safe alternatives?

A: The FDA has warned about compounded versions of these medications, as they may not meet the same quality and safety standards as FDA-approved products. Always discuss risks and benefits with your healthcare provider before considering compounded alternatives.

Q: Does insurance cover telehealth visits for weight-loss medication management?

A: Yes, most insurance plans now cover telehealth visits for obesity treatment equivalently to in-person visits, thanks to telehealth parity laws and expanded coverage following the pandemic.

Verified coverage status and pricing are accurate as of December 17, 2025. Always check your own insurance formulary for the latest details, as policies can change with new plan years.

Research Currency Statement

Verified as of December 17, 2025

Formularies checked: Aetna Clinical Policy (May 2024), Cigna Formulary (April 2024), Kaiser Permanente update (January 2025), Texas VDP criteria (March 2023), Pennsylvania Medicaid bulletin (August 2024)

Medicaid formularies verified: California DHCS (December 2025), Texas HHSC (March 2023), Florida (no Medicaid coverage per federal exclusion), New York NYRx PDL (October 2025), Pennsylvania DHS (December 2025), Illinois HFS (no coverage as of 2025)

GoodRx prices as of: December 2025 – Novo Nordisk/NovoCare program (effective November 2025), GoodRx press release (November 17, 2025), Lilly pricing updates (December 2025)

Citations

1. Aetna Clinical Policy Bulletin – Weight Loss GLP-1 Agonists. May 2024. www.aetna.com

2. California DHCS Medi-Cal Announcement. December 2025. www.cmadocs.org

3. Kaiser Family Foundation. ‘Medicaid Coverage of and Spending on GLP-1s.’ November 4, 2024. www.kff.org

4. GoodRx Press Release. ‘GoodRx Launches New Weight Loss Telemedicine Subscription.’ November 17, 2025. www.businesswire.com

5. Fierce Pharma. ‘Novo unveils newly reduced self-pay prices for Wegovy, Ozempic after White House deal.’ November-December 2025. www.fiercepharma.com

Source:

• https://www.aetna.com/products/rxnonmedicare/data/2024/WeightLoss%28BMI%2035%29GIP-GLP-1GLP-1AgonistsPAwithLimit6450-CUDR_05-2024.html#:~:text=%C2%B0Wegovy%3A%20Initial%20therapy%20DOA%3A%207,based%20on%20the%20following%20references
• https://www.singlecare.com/blog/cigna-prior-authorization-weight-loss/#:~:text=Cigna%20coverage%20criteria%20for%20GLP,drugs
• https://www.amwinsconnect.com/news/kaiser-permanenter-coverage-changes-glp-1-drugs-and-anti-obesity-medications-2025#:~:text=drugs%20and%20other%20AOMs%20will,with%20BMI%20less%20than%2040
• https://www.texaschildrenshealthplan.org/2023/04/28/provider-alert-non-formulary-requests-for-obesity-control-drugs#:~:text=for%20obesity%20control%20drugs%20for,Imcivree%2C%20Qysmia%2C%20Saxenda%20and%20Wegovy
• https://www.phlp.org/en/news/pennsylvania-medicaid-covers-newer-weight-loss-drugs#:~:text=Generally%2C%20to%20get%20these%20drugs,CDC%29%20charts
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=What%20You%20Need%20to%20Know%3A,Cal%20managed%20care
• https://solutionshortcut.com/medicaid-drug-coverage-by-state-2025-2026-updates/#:~:text=VDP%20PDL%20%26%20criteria%3B%20last,com
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=%2A%20Three%20GLP,covered%20after%20January%201%2C%202026
• https://www.forbes.com/sites/joshuacohen/2025/08/07/coverage-of-weight-loss-drugs-by-medicaid-plans-continues-to-lag/#:~:text=Medicaid%2C%20a%20federal,employees%20due%20to%20cost%20concerns
• https://www.fiercepharma.com/marketing/novo-unveils-newly-reduced-self-pay-prices-wegovy-ozempic-after-white-house-deal#:~:text=Novo%20revealed%20Monday%20that%20the,will%20still%20run%20for%20%24499